Arcus biosciences reports fourth-quarter and full-year 2023 financial results and provides a pipeline update

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting tigit, the adenosine axis (cd73 and a2a/a2b receptors), hif-2a, axl and pd-1 – across multiple.
RCUS Ratings Summary
RCUS Quant Ranking